Outcome base rates
What's normal — PI grant rate, infringement rate, revocation rate, settlement rate. Honest denominators using motion type.
Patentee win rate
Share of merits decisions where the patentee prevailed — infringement cases finding infringement, revocation cases upholding the patent. Settled, withdrawn, and procedural-only outcomes excluded from the denominator.
33%patentees prevail on the merits
3 merits decisions (small sample)
1 won · 2 lost · ↓ 100.0pp vs. prior 12 months
Win rate by year
Patentee win rate by year of first decision.
- 2024: 100% (1/1)
- 2025: 0% (0/2)
Win rate by division
Top divisions by merits-decision volume.
- Dusseldorf LD33%(n=3)
When patentees lose, why?
Of 2 losses…
50%
50%
Patent invalidated — 1 (50%)No infringement found — 1 (50%)
PI grant rate
—
PI grant rate (conservative)
—
Infringement rate
50%
1 infringed · 1 not infringed
Revocation rate
—
Settlement / withdrawal rate
Settled / withdrawn / dismissed as a share of all non-pending outcomes.
0% 0 / 3
Outcomes by category (detailed)
Stacked breakdown using sharper outcome enums — revocation cases split into revoked_full / revoked_partial / maintained_as_*, etc.
By technology sector
Top sectors by case count (filter scope applied).
By case category
How outcome rates differ across the six L2 buckets.
- Infringement3
By division
PI grant rate · infringement rate · revocation rate per division (within scope).
- Dusseldorf LD3 casesPI grant rate: —Infringement rate: 50%Revocation rate: —
Recent decisions
Most recent decisions in scope.
- 2025-07-30ACT_3932/2024Dusseldorf LDRevokedThe Düsseldorf Local Division dismissed Headwater Research LLC's infringement action against Samsung and revoked European patent EP 3 110 069 B1 to the extent of claim 1, on the basis of a successful counterclaim for revocation; all costs were borne by the claimant. The court also rejected a new argument on added matter as inadmissible under R. 9.2 RoP.
- 2025-05-13ACT_597355/2023Dusseldorf LDNot infringedThe Düsseldorf Local Division dismissed Sanofi and Regeneron's infringement action and Amgen's counterclaim for revocation concerning EP3536712 (a second medical use patent for evolocumab in paediatric patients), finding no infringement of the second medical use claim and that the counterclaim for revocation was also unfounded, with each side bearing the costs of the proceedings they lost.
- 2024-10-31ACT_580849/2023Dusseldorf LDPermanent injunctionThe Düsseldorf Local Division found that SodaStream's patent EP 1 793 917 was infringed by Aarke AB and issued an injunction along with ancillary relief. The defendant was ordered to bear the full costs of the litigation; the value in dispute was set at EUR 3,000,000.